Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.

Alexander P BenzLizhen XuJohn W EikelboomSaskia MiddeldorpTruman J MillingMark CrowtherPatrick YuePamela ConleyGenmin LuStuart J Connollynull null

Published in: Thrombosis and haemostasis (2022)

In patients with acute major bleeding on edoxaban, andexanet significantly decreased antifactor Xa activity. Hemostatic efficacy was similar to that observed in patients with bleeding on rivaroxaban or apixaban. Thrombotic events occurred at a rate expected in such patients.

Keyphrases

atrial fibrillation
venous thromboembolism
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
pulmonary embolism
replacement therapy